Clinical Study with BGB324, BerGenBio’s Selective First-in-Class AXL Inhibitor, Featured at the 2017 American Society of Hematology Annual Meeting

Bergen, Norway, 1 Nov 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces that data and analysis from its Phase Ib/II clinical trial with BGB324 in patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), has been selected for presentation at the 59th ASH Annual Meeting and Exposition in Atlanta, USA (9-12 Dec 2017).The presentation reports on the effect of BGB324 treatment on blood plasma proteins and their relationship to treatment outcome, as a